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Abstract
Background: Resistance to trastuzumab is a clinical problem, partly due to overriding activation of MAPK/PI3K signalling.
Sprouty-family proteins are negative regulators of MAPK/PI3K signalling, but their role in HER2-therapy resistance is
unknown.
Patients and Methods: Associations between Sprouty gene expression and clinicopathological features were investigated
in a breast cancer microarray meta-analysis. Changes in expression of Spry2 and feedback inhibition on trastuzumab
resistance were studied in SKBr3 and BT474 breast carcinoma cell lines using cell viability assays. Spry2 protein expression
was measured by quantitative immunofluorescence in a cohort of 122 patients treated with trastuzumab.
Results: Low gene expression of Spry2 was associated with increased pathological grade, high HER2 expression, and was a
significant independent prognostic factor. Overexpression of Spry2 in SKBr3s resulted in enhanced inhibition of cell viability
after trastuzumab treatment, and the PI3K-inhibitor LY294002 had a similar effect. Low Spry2 expression was associated
with increased risk of death (HR = 2.28, 95% CI 1.22–4.26; p = 0.008) in trastuzumab-treated patients, including in
multivariate analysis. Stratification of trastuzumab-treated patients using PTEN and Spry2 was superior to either marker in
isolation.
Conclusion: In breast cancers with deficient feedback inhibition, combinatorial therapy with negative regulators of growth
factor signalling may be an effective therapeutic strategy.
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Introduction
Although the HER2-targeting receptor tyrosine kinase (RTK)
inhibitor trastuzumab (Herceptin) has clinical efficacy in both early
and metastatic breast cancer, measurement of HER2 protein
expression or gene amplification status is a relatively poor predictor
of response with a low positive predictive value [1,2]. The
documented benefit of adjuvant trastuzumab combined with
chemotherapy versus chemotherapy alone in terms of overall
survival in HER2 positive patients is modest (96% vs 95%
respectively at 1 year [1] and 91% vs 87% respectively at 4 years
[2]). A large proportion of patients therefore unnecessarily receive
ineffective and expensive treatments with possible toxic side-effects.
Mechanisms of resistance must be elucidated in order to more
efficiently select patients who will respond to therapy. Suggested
mechanisms of de novo and acquired resistance to trastuzumab
include PIK3CA activating mutations, PTEN inactivation, IGF1R
over-expression and expression of p95 HER2 isoforms [3–5].
Although much attention has been paid to ‘forward-signalling’
mechanisms of pathway activation such as activating mutations in
cellular oncogenes (eg RAS, RAF or PIK3CA), it is as likely that loss of
negative feedback control also causes aberrant pathway activation,
as is the case with mutation or decreased protein expression of
PTEN. We hypothesised that one of the best characterised and
potent EGF-induced negative feedback regulators, the Sprouty-
family of proteins [6–12], may also be activated as a feedback
inhibition programme downstream of HER2 receptor, and
therefore contribute to sensitivity or resistance to trastuzumab.
To date there have been no reports implicating Sprouty in
therapeutic sensitivity or resistance. The only published report of
expression of Sprouty in breast cancer showed decreased
expression at transcript level of Spry1 and Spry2 in 78% and
96% respectively of a small panel of breast cancers (n = 50) [13]. In
spite of persistent attempts to establish the underlying mechanism
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23772
for decreased expression, the exact cause remains elusive and may
be different for specific orthologues in different cancers. In prostate
cancer, there is conflicting evidence regarding the epigenetic
regulation of Spry1, Spry2 and Spry4, with some authors showing
that Spry2 and Spry4 are downregulated by hypermethylation
[14,15], although in a separate study no hypermethylation of the
promoter region of Spry2 was identified [16]. Likewise, loss of
heterozygosity (LOH) of Spry2 on chromosome 13 has been found
in prostate cancer [14], but not in other cancers. In breast cancer,
none of the Sprouty family members are downregulated by either
LOH or epigenetic mechanisms [13]. Given the dynamic nature of
Sprouty expression in response to ligand drive, it is possible that
detection of low expression levels reflects the activation state of the
signalling network rather than a genetic or epigenetic phenome-
non.
Our objectives were to (1) investigate whether Sprouty 2
expression is associated with established clinicopathological
parameters, including prognosis, in breast cancer, and (2) establish
what role, if any, Sprouty 2 expression levels play in therapeutic
resistance and sensitivity to trastuzumab.
Methods
Ethics statement
The study was approved by the Lothian Research Ethics
Committee (08/S1101/41). No informed consent (written or
verbal) was obtained for use of retrospective tissue samples from
the patients within this study, most of whom were deceased, since
this was not deemed necessary by the Ethics Committee, who
waived the need for consent. All samples were anonymised.
Gene expression microarray meta-analysis of Sprouty 1, 2
and 4
A meta-analysis of six Affymetrix gene expression datasets
comprising a total of 1,107 primary human breast cancers was
performed as previously described [17]. Patient grade and follow-
up information was retrieved from the original studies [18–23],
and clinicopathological characteristics for the dataset are summa-
rised in Table 1. The follow-up endpoints for the Chin et al.,
Pawitan et al. and Sotoriou et al. datasets were recurrence-free
survival and for Desmedt et al., Ivshina et al. and Wang et al.
datasets it was disease-free survival. Gene expression levels of
Sprouty family genes were also investigated in the datasets of Chen
et al. and Lu et al. to compare gene expression with normal breast
tissue and HER2 immunohistochemical status, respectively
[24,25]. The Affymetrix probesets studied were SPRY1
(212558_at), SPRY2 (204011_at), SPRY4 (221489_s_at), HER2
(216836_s_at).
Cell culture
Cell lines were obtained from ATCC. SKBr3 and BT474 breast
adenocarcinoma cell lines were grown as monolayer cultures in
DMEM supplemented with 10% heat-inactivated foetal calf serum
(FCS) and penicillin/streptomycin (100 IU/mL) in a humidified
atmosphere of 5% CO2 at 37uC.
Constructs, transfection, and cell viability
The FLAG-hSpry2 and FLAG-HSpry2Y55F constructs were a
kind gift from Dr Graeme Guy (Signal Transduction Laboratory,
Institute of Molecular and Cell Biology, National University of
Singapore) and used as previously described [26,27]. In addition,
empty pXJ40FLAG vector was constructed by digesting hSpry2-
containing pXJ40FLAG vector at BamH1 and BglII restriction
sites. Both mutant and normal sequences were verified by DNA
sequencing, and empty vector confirmed by gel electrophoresis. At
70% confluence, cells were transfected with 1–2 mg of FLAG-
tagged plasmid DNA using Lipofectamine 2000 reagent (Invitro-
gen) according to the manufacturer’s instructions. On the
following day, the cells were trypsinised and plated into 96-well
plates at a concentration of 1000 cells/well. The cells were treated
with or without trastuzumab (10 mg/ml) for 24 or 48 h. Cell
viability was measured using the AlamarBlue reagent (AbD
Serotec), according to manufacturer’s instructions.
Samples and tissue microarray construction
The population characteristics of the retrospective trastuzumab-
treated cohort are summarised in Table 1 and have been described
previously [28]. HER2 gene amplification status was determined
by fluorescence in situ hybridisation (FISH; DAKO HER2 FISH
PharmDx, Ely, Cambridgeshire). Overall survival was calculated
from date of initial diagnosis to date of death by any cause.
Following H&E sectioning of representative tumour blocks,
tumour areas were marked for TMA construction and 0.6 mm2
cores placed into 3 separate TMA replicates for each sample, as
previously described [29].
Immunofluorescence and AQUA automated image
analysis
A detailed description of the AQUA HistoRx methodology is
available elsewhere [30,31]. Briefly, slides were incubated with
primary antibodies diluted in 0.025% PBST for 1 h at room
temperature (AE1/AE3 mouse monoclonal cytokeratin antibody,
rabbit polyclonal to hSpry2 (Novus Biologicals diluted 1:100 and
1:25 respectively). Pan-cytokeratin antibody was used to identify
infiltrating tumour cells and normal epithelial cells, DAPI-
counterstain to identify nuclei, and Cy-5-tyramide detection for
target (hSpry2) for compartmentalised (tissue and subcellular)
analysis of tissue sections. Antibody specificity for hSpry2 antibody
was determined by a single band on western blot, positive tissue
controls, and localisation in the epithelial compartment, together
with omission of primary antibody as a negative control. Only
invasive tumour areas were included in the analysis; areas of in situ
disease or normal epithelium were excluded by masking prior to
analysis.
Study design and Statistics
REMARK guidelines were adhered to where possible [32]. The
biomarker analysis was a retrospective cohort study, with a fixed
sample sizes and the study not designed to detect an overall effect
size. No stratification or matching were used. Both cohorts used
within this study have been described elsewhere [17,20]. Median
follow up for the gene expression metadata was 7.4 years (range 0–
23.9 years) and the trastuzumab-treated cohort 1.8 years (range 0–
66.8). Comparison of gene expression groups were by Mann-
Whitney test for two independent groups and Kruskal Wallis test for
more than two groups. AQUA scores were averaged from replicate
cores, and cores containing ,5% malignant epithelium were
excluded. We used the software programme, X-Tile, to determine
the optimal cutpoint while correcting for the use of minimum P
statistics [33], which is known to inflate type I error when used
incorrectly [34]. Two methods of statistical correction for the use of
minimal P approach were utilised: the first by calculation of aMonte
Carlo P-value and the second using the Miller-Siegmund minimal P
correction [34]. Overall survival was subsequently assessed by
Kaplan-Meier analysis with log-rank for determining statistical
significance. Relative risk was assessed by the univariate and
multivariate Cox proportional hazards model. All calculations and
Sprouty 2 in Breast Cancer
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Table 1. Clinicopathological characteristics of patients analysed in this study.
Cohort variable Cohort 1 Cohort 2
Number Percentage Log-rank p-value Number Percentage Log-rank p-value
Age, years 0.30 0.46
,50 263 23.8 49 40.1
.50 398 36.0 73 59.9
NK 446 40.3 0 0
NPI 0.22
,3.4 - - 2 1.6
3.4–5.4 - - 47 38.5
.5.4 - - 62 50.8
NK - - 11 9.0
Grade ,0.0001 0.80
1 167 15.1 1 0.8
2 330 29.8 19 15.6
3 287 25.9 99 81.1
NK 323 29.2 3 1.6
Tumour Stage ,0.0001 0.024
1 338 30.5 35 28.7
2 309 27.9 64 52.5
3 15 1.4 12 9.8
4 445 40.2 3 2.5
NK 0 0 8 6.6
Node stage at diagnosis ,0.0001 0.20
Negative 780 70.5 26 21.3
Positive 157 14.2 87 71.3
NK 170 15.4 9 7.4
Molecular phenotype 0.061
Basal 172 15.5 - -
Luminal A 336 30.4 - -
Luminal B 161 14.5 - -
HER2 194 17.5 - -
Normal-like 244 22.0 - -
ER status 0.220 0.038
.3 239 21.6 72 59.0
#3 700 63.2 41 33.6
NK 168 15.2 9 7.3
HER2 status 0.38
Positive - - 90 73.7
Negative - - 32 26.3
NK - - 0 0
Chemotherapy ,0.0001
Anthracycline-containing - - 66 54.1
Taxane-containing - - 53 43.4
NK - - 3 2.5
Cohort 1 is the gene expression cohort, and cohort 2 is the trastuzumab-treated cohort. NPI =Nottingham Prognostic Index.
doi:10.1371/journal.pone.0023772.t001
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analyses were two-tailed where appropriate and performed using
SPSS 14.0 for Windows (SPSS, Inc., Chicago IL).
Results
Spry2 is differentially expressed across
clinicopathological subgroups of breast cancer and is an
independent prognostic factor
We first performed a meta-analysis of six published breast
cancer gene expression profiles representing a total of 1107
tumours to assess the gene expression of Spry1, Spry2 and Spry4.
Spry3 was omitted from the analysis since this is considered a minor
orthologue, transcript levels are low across published datasets, and
it is not represented on the Affymetrix U133A GeneChip. Sprouty
family genes were differentially expressed across the five intrinsic
breast cancer subtypes [35], with high expression of Spry 1 and
Spry2 in normal-like cancers and higher expression of Spry4 in
basal-like and normal-like cancers (Figure 1A). Higher grade
tumours had lower expression of Spry1 and Spry2 (Figure 1B). To
investigate the association of Sprouty transcript with clinicopath-
ological variables further, we analysed two further gene expression
datasets. Spry2 gene expression was found to be lower in a panel of
invasive ductal carcinomas compared to normal breast tissue, and
lower in HER2-positive (by immunohistochemistry) tumours
(Figures 1C and 1D). Although the tumours in the meta-dataset
did not have individual HER2 IHC status, separating them
according to an upper quartile gene expression cut-point (25%
‘HER2-high’) confirmed that tumours with high expression of
HER2 have significantly (p = 0.02) lower Sprouty 2 (Figure 2).
Although the highest Spry2 expression levels were observed in
those tumours with low HER2 gene expression (Figure 2), there
was still a wide range of expression of Spry2 in HER2-high tumours
(Figure 2). We therefore speculated that Sprouty 2 could have an
impact on therapeutic response to trastuzumab and act as a
potential predictive factor.
First, however, we were keen to determine whether Sprouty 2
could be used as a prognostic factor, independent of other
clinicopathological parameters. High Spry2 gene expression was
consistently associated with better prognosis (optimal cutpoint HR
1.49, 96% CIs 1.21–1.84, p,0.0001), particularly in those
tumours expressing very high levels of Spry2 (HR 2.71, 95% CIs
1.34–5.46, p= 0.005), consistent with the accepted role of Sprouty
2 as a tumour suppressor gene (Figure 3). Higher stage, grade and
node status were associated with poorer survival in univariate
analysis (Table 1); in multivariate analysis, stage, grade and Spry2
expression remained significant prognostic variables (Spry2 HR
1.33, 95% CIs 1.02–1.74, p = 0.04; stage HR 1.4, 95% CIs 1.12–
1.82, p = 0.005; grade HR 1.20, 95% CIs 1.00–1.44, p = 0.05).
Sprouty 2 may therefore identity patients with a more favourable
outcome, even when tumours exhibit poor pathological features.
Spry2 expression acts synergistically with trastuzumab to
reduce cell viability in vitro: Forced feedback inhibition
with chemical inhibitors has a similar effect
Since Spry2 was most closely associated with HER2 status, we
next investigated what the effect of altering steady-state expression
of Spry2 was on cell growth and therapeutic response, using
transient expression of wild-type and dominant negative
Spry2Y55F. Transfection efficiencies and endogenous expression
levels are demonstrated in Figure S1. SKBr3 breast adenocarci-
noma cell lines were insensitive to treatment with trastuzumab,
while BT474s were sensitive at 48 h (Figure 4) when grown in full
serum conditions. Overexpression of empty vector, Spry2, or
Spry2Y55F dominant negative construct resulted in no significant
changes in growth in either of the cell lines at 48 h. However,
overexpression of Spry2 significantly increased sensitivity to
trastuzumab at 48 h in trastuzumab-insensitive SKBr3s, but there
was no difference in growth in BT474s with either the full length
or dominant-negative constructs. Re-establishing feedback inhibi-
tion in Sprouty-low tumours may therefore be an effective strategy
for combinatorial therapy with trastuzumab, and raises the
possibility that in some HER2 overexpressing tumours, high
expression of Spry2 may be a marker of response to trastuzumab.
We tested the combinatorial approach in vitro by substituting the
negative feedback control of ERK and PI3K signalling of Spry2
with the chemical inhibitors LY294002 and PD98059, which
inhibit PI3K and MEK1 respectively, with and without treatment
with trastuzumab. As expected, trastuzumab showed little effect on
cell viability alone, but a synergistic effect when SKBr3 cells were
pretreated with LY294002, inhibiting growth by 29% at 24 hours
(Figure 4). Forcing feedback inhibition through combinatorial
approaches may therefore be a novel therapeutic strategy in
tumours with a priori trastuzumab resistance.
Low Spry2 expression is associated with poor outcome in
trastuzumab-treated patients
Since higher levels of Spry2 were associated with increased
therapeutic efficacy in the HER2+ SKBr3 breast cell line, we
quantified expression of Spry2 in 122 primary breast tumours
from patients who had been treated with trastuzumab using the
AQUA fluorescence image analysis system ([28] and Figure 5A).
This allowed us to test whether high expression levels of Spry2
protein were associated with clinical outcome in patients treated
with trastuzumab in the clinical setting. The cut-point for Spry2
expression were calculated as described in the Materials and
Methods, such that as well as showing high significance for
difference in survival (p = 0.0069; Figure 5B), the cutpoint for
Spry2 expression also maintained near significance with Monte
Carlo simulations (p = 0.09) and correction for type I error (Miller-
Seigmund p value = 0.12). In univariate analysis, tumour size, ER
status, chemotherapy regimen, and Spry2 expression levels were
all associated with significant survival differences (log-rank test,
p,0.05, table 1), but Spry2 remained the only significant
predictor of survival in multivariate analysis (Cox logistic
regression, p = 0.002). Lymph node status was not significant in
univariate analysis, most likely due to the low numbers of node-
negative patients available for analysis in this high-risk population.
High levels of Spry2 expression were associated with better overall
survival than patients with tumours which expressed low levels of
Spry2 (HR=2.28, 95% CI 1.22–4.26; p = 0.008; mean survival 48
(95% CI 41–54 months) months vs 37 (95% CI 26–40 months)
months for high and low Spry2 levels, respectively). This supports
the role of Spry2 as a tumour suppressor gene in breast cancer,
and its role in therapeutic resistance to trastuzumab.
Finally, since we have previously established that quantitative
PTEN expression is also associated with outcome in the same
cohort of trastuzumab-treated patients [28], and Sprouty 2 may
exert some of its effects either directly or indirectly via PTEN [36],
we reasoned that we could improve the predictive algorithm by
considering the expression of both Sprouty 2 and PTEN. Protein
expression of Sprouty 2 and PTEN were significantly correlated
(Spearman’s rank correlation coefficient 0.40, p,0.0001). In
survival analysis, tumours expressing both high PTEN and high
Sprouty 2 had the best outcome (mean survival 51 months),
whereas those tumours expressing either PTEN or Sprouty 2
alone, or neither, had poorer outcomes (40, 24, and 32 months
respectively). The relative risk of death in the Sprouty 2/PTEN
Sprouty 2 in Breast Cancer
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high group was higher than either marker alone (RR 3.7; 95% CI
1.7–7.8, p= 0.001). When stratifying patients for trastuzumab
therapy, there may therefore be increased value in combined
measurement of pathway biomarkers.
Discussion
The balance between positive and negative signals is critical in
the maintenance of normal cell homeostasis in response to external
stimuli, whether the stimulus is physiological (such as ligand drive)
or therapeutic (such as with RTK or small molecule inhibitors of
cellular signalling). The clinical implications of feedback control
are becoming more readily appreciated. Loss of feedback
inhibition in tumours treated with mTOR inhibitors (via increased
expression of IRS-1) results in induction of AKT signalling, and
may be responsible for the disappointing efficacy of mTOR
antagonists in the clinic [37]. At worst, mechanisms such as
unintended negative feedback contribute to the poor efficacy of
agents when studied in Phase II and Phase III cancer trials and the
high rate of attrition of drugs (approximately 30% due to efficacy),
which is both time consuming and expensive [38].
Here we investigated the role of Sprouty-mediated feedback
mechanism in breast cancer and its possible involvement in
therapeutic resistance to RTK-inhibitors. In breast cancer, Spry2
has been shown to be down-regulated at gene expression level
compared to normal breast epithelium [13], which we confirmed
in a meta-analysis of published gene expression data. Also
consistent with its tumour suppressor function, Spry2 expression
Figure 1. Gene expression of Sprouty-family members in relation to clinicopathological parameters; subtype (A), grade (B), HER2
status (C) and compared to normal breast tissue (D) in a meta-analysis of 1107 breast carcinomas [17] (A and B) or in single datasets
(C and D) [24,25].
doi:10.1371/journal.pone.0023772.g001
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decreases with increasing histological grade, and shows a strong
association with relapse-free survival in a meta-analysis of over one
thousand primary breast carcinomas, including in multivariate
analysis. Sprouty 2 may therefore be a useful biomarker to stratify
patients who are at very low risk of relapse and might not require
adjuvant chemotherapy, even when there are other poor
pathological prognostic features.
Since Sprouty expression was associated with HER2 status in
our meta-analysis and has been shown to be expressed as a delayed
early response (DER) gene downstream of other closely related
growth factor receptors such as EGFR and FGFR, we further
explored the association with HER2 in order to establish whether
Sprouty plays an important role downstream of this therapeuti-
cally-targeted receptor. We explored the co-operativity of feedback
by Sprouty on overcoming therapeutic resistance to trastuzumab
by overexpressing Spry2 or dominant negative Spry2Y55F in
trastuzumab-resistant or sensitive cell lines expressing intermedi-
ate-levels of endogenous Spry2. Full length Spry2 synergised with
trastuzumab to inhibit growth in trastuzumab insensitive SkBr3
cells. In some settings, therefore, reinstating negative feedback can
overcome trastuzumab resistance. Since no Sprouty mimetics exist
for therapeutic purposes, we used inhibitors of PI3K and ERK
signalling, LY294002 and PD98059 in place of Spry2 feedback,
since Spry2 can inhibit ERK directly or PI3K indirectly via PTEN
[36]. LY294002, but not PD98059, synergised with trastuzumab
to inhibit cell growth, suggesting that for cellular proliferation at
least, inhibition through PI3K is the dominant synergistic feedback
mechanism.
The link between Sprouty 2 expression and therapeutic
response was further investigated in a clinical cohort of metastatic
breast cancers treated with trastuzumab. Quantitative protein
expression levels of Spry2 stratified patients for outcome in a series
of 122 trastuzumab-treated breast cancers. Low Spry2 levels
significantly correlated with decreased overall survival in multi-
variate analysis. Furthermore, when an integrated analysis of
protein expression of PTEN and Sprouty 2 was performed,
combined high expression of both biomarkers was superior to
expression of each alone, or neither, in stratifying patients in the
Figure 2. Relationship between HER2 and Spry2 gene expression. Spry2 shows a wide range of expression in both HER2 high and low (split at
the upper quartile) expressing tumours (A). On average, tumours expressing high levels of HER2 have decreased Spry2 expression levels (B).
doi:10.1371/journal.pone.0023772.g002
Figure 3. Prognostic significance of Spry2 expression. Patients with high expression (green lines) of Spry2 have the best prognosis, with very
high expressers showing the most favourable outcomes.
doi:10.1371/journal.pone.0023772.g003
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Figure 4. The effects of Sprouty 2 expression on response to trastuzumab in vitro. (A) Cell viability (AlamarBlue) assays to assess the effect
of Spry2 on sensitivity to trastuzumab in trastuzumab resistant SKBr3s (left panel) and trastuzumab sensitive BT474s (right panel). Values are % cell
viability compared to untreated controls. Expression of full length Spry2 results in a significant decrease in cell viability (asterisk, Student’s t-test,
p = 0.0008) compared to control or dominant negative Spry2Y55F. (B) Trastuzumab and LY294002 show synergistic inhibition of cell viability (asterisk,
Student’s t-test, p = 0.042) in trastuzumab-resistant SKBr3 breast cell lines.
doi:10.1371/journal.pone.0023772.g004
Figure 5. Quantitative expression of Spry2 is associated with trastuzumab sensitivity in patients. (A) AQUA fluorescent analysis of Spry2
expression in a tissue microarray core, showing cytoplasmic localisation of Spry2 (red) and masking of tumour areas for quantitation by cytokeratin
(green). (B) Kaplan-Meier survival curves for patients treated with trastuzumab for low (blue) and high (green) protein expression of Spry2. (C) Kaplan-
Meier survival curves for PTEN/SPRY2 high (purple), PTEN high (beige), Spry2 high (green) and PTEN/SPRY2 low (blue) patients. Overall survival is
calculated from time of initial diagnosis to date of death.
doi:10.1371/journal.pone.0023772.g005
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trastuzumab-treated cohort. This might reflect the role that
Sprouty 2 plays in inhibiting PI3K signalling via PTEN [36].
Therefore, multiple biomarkers which capture multiple pathway
control mechanisms may be superior to single biomarkers alone.
In conclusion, our data suggest that in a proportion of breast
tumours deficient in negative feedback, combinatorial therapy
with inhibitors of pathways downstream of RTKs may be an
effective therapeutic strategy, and negative feedback proteins such
as Sprouty may be useful biomarkers for selecting patients for
these therapies.
Supporting Information
Figure S1 Transfection efficiency of S2 and Y55F
constructs (A) and endogenous expression of Spry2 (B)
in BT474 and SKBr3 breast cancer cell lines. Cell lines
were transiently transfected with increasing concentrations of
DNA (measured in mg) in 6-well plates, and immunoblotted with
anti-FLAG or anti-hSpry2 antibodies. Since endogenous expres-
sion was much lower than transfected expression, blots were re-
probed with a longer exposure time (B) in order to compare
protein expression of Spry2, which was similar in both cell lines.
(PPT)
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